Astrazeneca Pharma India Ltd vs Divis Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Astrazeneca Pharma India Ltd is ₹ 8369 as of 06 May 16:01 . The P/E Ratio of Astrazeneca Pharma India Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Divis Laboratories Ltd changed from 48.6 on March 2021 to 69.8 on March 2025 . This represents a CAGR of 7.51% over 5 years The Market Cap of Astrazeneca Pharma India Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Divis Laboratories Ltd changed from ₹ 96366 crore on March 2021 to ₹ 153257 crore on March 2025 . This represents a CAGR of 9.72% over 5 years The revenue of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Divis Laboratories Ltd for the Dec '25 is ₹ 2692 crore as compare to the Sep '25 revenue of ₹ 2860 crore. This represent the decline of -5.87% The ebitda of Astrazeneca Pharma India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Divis Laboratories Ltd for the Dec '25 is ₹ 904 crore as compare to the Sep '25 ebitda of ₹ 1033 crore. This represent the decline of -12.49% The net profit of Astrazeneca Pharma India Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Divis Laboratories Ltd changed from ₹ 430 crore to ₹ 583 crore over 7 quarters. This represents a CAGR of 19.00% The Dividend Payout of Astrazeneca Pharma India Ltd changed from 5.36 % on March 2021 to 69.12 % on March 2025 . This represents a CAGR of 66.76% over 5 yearsThe Dividend Payout of Divis Laboratories Ltd changed from 27.16 % on March 2021 to 35.99 % on March 2025 . This represents a CAGR of 5.79% over 5 years .

About Astrazeneca Pharma India Ltd

AstraZeneca Pharma India Limited (APIL) was incorporated on July 11, 1979.
The Company is engaged in the business of manufacture, distribution and marketing of pharmaceutical products and co-ordinates clinical trial services with an overseas group company.
The major therapy areas where the company operates are Onocology, Alimentary & Metabolism, Cardio Vascular, Renal, Diabetes, Respiratory and Oncology. AstraZeneca Pharma India, formerly known as Astra-IDL (AIL), was an erstwhile joint venture of Astra Zeneca, UK and Hinduja controlled IDL. Astra Pharmaceuticals AB, Sweden acquired all of the 1287500 equity shares in the Company of IDL, representing 25.75% of the Company's issued and paid up equity share capital.
Consequently, the Company became a subsidiary of Astra, which is a direct wholly owned subsidiary of Astra AB, Sweden (now known as AstraZeneca Pharmaceuticals AB Sweden) and an indirect wholly owned subsidiary of AstraZeneca Plc, the Group parent Company.

About Divis Laboratories Ltd

Divi's Laboratories Limited is one of the leading pharmaceutical companies in the world, manufacturing Active Pharmaceutical Ingredients (APIs), Intermediates and Nutraceuticals.
The Company is one of the world's largest API companies, with two manufacturing units and a market presence across 100 countries.
It is engaged in the manufacture of Active Pharmaceutical ingredients (API's), Intermediates and Nutraceutical ingredients with predominance in exports.
In addition to generic business, the Company, through its custom synthesis business, supports innovator pharma companies for their patented products business right from gram scale requirements for clinical trials to launch as well as late life cycle management.
It is among the largest pharmaceutical companies in India with a portfolio of approx.

FAQs for the comparison of Astrazeneca Pharma India Ltd and Divis Laboratories Ltd

Which company has a larger market capitalization, Astrazeneca Pharma India Ltd or Divis Laboratories Ltd?

Market cap of Astrazeneca Pharma India Ltd is 20,583 Cr while Market cap of Divis Laboratories Ltd is 176,617 Cr

What are the key factors driving the stock performance of Astrazeneca Pharma India Ltd and Divis Laboratories Ltd?

The stock performance of Astrazeneca Pharma India Ltd and Divis Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Astrazeneca Pharma India Ltd and Divis Laboratories Ltd?

As of May 6, 2026, the Astrazeneca Pharma India Ltd stock price is INR ₹8233.5. On the other hand, Divis Laboratories Ltd stock price is INR ₹6653.05.

How do dividend payouts of Astrazeneca Pharma India Ltd and Divis Laboratories Ltd compare?

To compare the dividend payouts of Astrazeneca Pharma India Ltd and Divis Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.